 Cecilia Low Wang
Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 6 | 2022 | 2041 | 1.550 |
Why?
| | Diabetes Mellitus | 4 | 2021 | 969 | 1.390 |
Why?
| | Cardiovascular System | 2 | 2019 | 113 | 1.350 |
Why?
| | Lower Extremity | 3 | 2021 | 257 | 1.340 |
Why?
| | Peripheral Arterial Disease | 3 | 2021 | 312 | 1.160 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 375 | 1.140 |
Why?
| | Hyperglycemia | 3 | 2016 | 336 | 0.990 |
Why?
| | Hypoglycemic Agents | 3 | 2022 | 1044 | 0.950 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 388 | 0.860 |
Why?
| | Epidemics | 1 | 2021 | 64 | 0.820 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 1711 | 0.770 |
Why?
| | Drug Approval | 1 | 2019 | 72 | 0.750 |
Why?
| | Early Termination of Clinical Trials | 1 | 2018 | 15 | 0.740 |
Why?
| | Sample Size | 1 | 2018 | 105 | 0.710 |
Why?
| | Blood Glucose | 2 | 2019 | 1940 | 0.710 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 246 | 0.690 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1009 | 0.660 |
Why?
| | Atherosclerosis | 2 | 2017 | 306 | 0.640 |
Why?
| | Ischemia | 1 | 2018 | 314 | 0.610 |
Why?
| | Hospitals | 2 | 2017 | 468 | 0.600 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 40 | 0.600 |
Why?
| | Drugs, Investigational | 1 | 2015 | 22 | 0.600 |
Why?
| | Aspirin | 1 | 2018 | 317 | 0.590 |
Why?
| | Endovascular Procedures | 1 | 2018 | 187 | 0.580 |
Why?
| | Patient Care Planning | 1 | 2016 | 166 | 0.570 |
Why?
| | Patient Selection | 1 | 2018 | 694 | 0.540 |
Why?
| | Glucocorticoids | 2 | 2016 | 539 | 0.530 |
Why?
| | Swine, Miniature | 1 | 2013 | 77 | 0.510 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 352 | 0.460 |
Why?
| | Hospitalization | 2 | 2016 | 1678 | 0.410 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 385 | 0.370 |
Why?
| | Insulin Resistance | 2 | 2015 | 1148 | 0.370 |
Why?
| | Algorithms | 1 | 2016 | 1558 | 0.360 |
Why?
| | Heart Failure | 1 | 2016 | 1899 | 0.260 |
Why?
| | Insulin | 1 | 2013 | 2189 | 0.240 |
Why?
| | Humans | 15 | 2022 | 113846 | 0.240 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 71 | 0.230 |
Why?
| | Treatment Outcome | 4 | 2019 | 9002 | 0.230 |
Why?
| | Amputation | 1 | 2021 | 169 | 0.200 |
Why?
| | Risk Factors | 3 | 2019 | 9050 | 0.200 |
Why?
| | Obesity | 1 | 2013 | 2627 | 0.200 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 210 | 0.180 |
Why?
| | Hypercholesterolemia | 1 | 2017 | 103 | 0.170 |
Why?
| | Diet | 2 | 2015 | 1078 | 0.160 |
Why?
| | Anticholesteremic Agents | 1 | 2017 | 135 | 0.150 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 78 | 0.150 |
Why?
| | Quality of Health Care | 1 | 2021 | 643 | 0.150 |
Why?
| | Nausea | 1 | 2015 | 116 | 0.150 |
Why?
| | Male | 8 | 2021 | 60993 | 0.150 |
Why?
| | Mexican Americans | 1 | 2015 | 92 | 0.140 |
Why?
| | Female | 8 | 2021 | 63035 | 0.140 |
Why?
| | United States | 3 | 2021 | 12329 | 0.140 |
Why?
| | Adiponectin | 1 | 2015 | 214 | 0.140 |
Why?
| | Double-Blind Method | 1 | 2018 | 1673 | 0.130 |
Why?
| | Lactic Acid | 1 | 2015 | 301 | 0.130 |
Why?
| | Insulin, Isophane | 1 | 2013 | 19 | 0.130 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2013 | 58 | 0.130 |
Why?
| | Aged | 4 | 2021 | 20109 | 0.130 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 76 | 0.120 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 200 | 0.120 |
Why?
| | Enteral Nutrition | 1 | 2013 | 156 | 0.110 |
Why?
| | Renal Insufficiency | 1 | 2013 | 124 | 0.110 |
Why?
| | Disease Management | 1 | 2016 | 606 | 0.110 |
Why?
| | Patient Care Team | 1 | 2016 | 532 | 0.110 |
Why?
| | Arteries | 1 | 2013 | 238 | 0.110 |
Why?
| | Quality of Life | 1 | 2022 | 2136 | 0.110 |
Why?
| | Adiposity | 1 | 2015 | 493 | 0.110 |
Why?
| | Biomarkers | 2 | 2019 | 3501 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2013 | 249 | 0.110 |
Why?
| | Swine | 1 | 2013 | 716 | 0.110 |
Why?
| | Postoperative Complications | 1 | 2021 | 2116 | 0.100 |
Why?
| | Middle Aged | 4 | 2018 | 28753 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2229 | 0.100 |
Why?
| | Vasodilation | 1 | 2013 | 476 | 0.100 |
Why?
| | Renal Dialysis | 1 | 2013 | 329 | 0.100 |
Why?
| | Risk Assessment | 1 | 2019 | 3147 | 0.100 |
Why?
| | Phosphorylation | 1 | 2013 | 1742 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3910 | 0.060 |
Why?
| | Adolescent | 2 | 2015 | 18736 | 0.050 |
Why?
| | Global Health | 1 | 2021 | 339 | 0.050 |
Why?
| | Plaque, Atherosclerotic | 1 | 2017 | 38 | 0.040 |
Why?
| | Survival Rate | 1 | 2021 | 1854 | 0.040 |
Why?
| | Diet Surveys | 1 | 2015 | 82 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2017 | 334 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2015 | 219 | 0.040 |
Why?
| | Incidence | 1 | 2021 | 2470 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 634 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4906 | 0.030 |
Why?
| | Self Report | 1 | 2015 | 684 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1302 | 0.030 |
Why?
| | Animals | 1 | 2013 | 35394 | 0.030 |
Why?
| | Prospective Studies | 1 | 2021 | 6250 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4275 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4581 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2016 | 6796 | 0.020 |
Why?
| | Adult | 2 | 2016 | 31979 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2016 | 11340 | 0.010 |
Why?
| | Young Adult | 1 | 2015 | 10971 | 0.010 |
Why?
|
|
Low Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|